Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform

Novartis has agreed to acquire Myricx Bio for up to $1.5 billion ($1.1 billion upfront plus milestone payments) to advance next-generation antibody-drug conjugate (ADC) payloads using Myricx's novel N-myristoyltransferase inhibitor (NMTi) platform. The acquisition combines Novartis's oncology expertise with Myricx's differentiated ADC assets targeting solid tumors, addressing unmet needs in overcoming ADC resistance and improving tolerability.